Codice QR

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study

Abstract Daratumumab is approved for patients with multiple myeloma (MM) and high-risk smoldering MM (HR-SMM). However, HR-SMM is often as genomically complex as MM, suggesting it may be too advanced for single-agent intervention. We report on a Phase II trial of single-agent daratumumab in patients...

Descrizione completa

Salvato in:
Autori principali: Omar Nadeem, Michelle P. Aranha, Robert A. Redd, Michael Koontz, Jeffrey V. Matous, Andrew J. Yee, Jeffrey A. Zonder, Andrew Kin, Sophie Magidson, Elizabeth D. Lightbody, Ting Wu, Floris Chabrun, Jean-Baptiste Alberge, Ankit K. Dutta, Jacqueline Perry, Ashlee Sturtevant, Mahshid Rahmat, Junko Tsuji, Christine Davie, Caroline Ricciardi, Frances Arters, Marjorie Marto, Amy Bergeron, Jacalyn Rosenblatt, Elizabeth K. O’Donnell, Tarek H. Mouhieddine, Lorena Pantano, Jacob P. Laubach, Paul G. Richardson, Gad Getz, Lorenzo Trippa, Romanos Sklavenitis-Pistofidis, Irene M. Ghobrial
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Portfolio 2026-04-01
Serie:Nature Communications
Accesso online:https://doi.org/10.1038/s41467-026-71483-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi